# Albemarle Corporation (ALB)

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-28  
**Report type:** Primer (steps 1–3 of 19)  
**API endpoint:** GET /api/v1/research/ALB/primer

## Business Model

---
step: "01"
title: "Business Model & Value Chain"
ticker: ALB
company: "Albemarle Corporation"
source: coverage-next-full
created: 2026-05-28
---

### Step 01 — Business Model & Value Chain: Albemarle Corporation (ALB)

#### Key Findings

- ALB is a **vertically integrated lithium + bromine specialty chemicals producer**, with ~75–80% of normalized revenue from the Energy Storage (lithium) segment and ~18–20% from Specialties (bromine) [S1][S2].
- The Ketjen refining-catalyst segment (~$1.0–1.1B revenue at peak) was **divested in March 2026** for combined proceeds of ~$670M (Ketjen sale to KPS Capital Partners + 50% Eurecat JV stake to Axens) [S3]. Post-divestiture, ALB is a focused 2-segment operator.
- Value chain depth: ALB controls the full lithium chain from **resource extraction** (Atacama brine, Chile; Greenbushes/Wodgina hard rock, Australia) through **conversion** (LiOH, Li₂CO₃ at Kemerton, La Negra, China JVs) to **specialty compounds** for Tier-1 battery OEMs [S2].
- **Net signal: mixed.** Business is simpler post-Ketjen; the lithium franchise is genuinely world-scale, but exposure to commodity-price cycles is now structurally higher than during the diversified era.

#### Implications for Thesis and Valuation

ALB's business is best analyzed as **two stacked businesses**:
1. A high-beta, commodity-price-sensitive **lithium franchise** (Energy Storage) whose EBITDA can swing from ~$4B (FY2022) to negative (FY2024) on the same asset base.
2. A stable **bromine oligopoly** (Specialties) generating ~$250–350M of segment EBITDA at mid-cycle, providing a real cash-flow floor.

Valuation must therefore use a **sum-of-the-parts** lens: a mid-cycle multiple on the lithium franchise plus a stable specialty-chemical multiple on Specialties. A single blended P/E is uninformative through the cycle.

#### Objective

Map ALB's segments, products, customer base, supply chain, and competitive position to define the analytical framework used throughout the report.

#### Narrative Analysis

**Segment 1 — Energy Storage (lithium):** ALB sells lithium hydroxide (LiOH, used in nickel-rich NMC and NCA cathodes for EVs), lithium carbonate (Li₂CO₃, LFP cathodes and consumer electronics), and lithium chloride/specialty grades [S2]. Customers are Tier-1 cell makers (LG Energy Solution, Panasonic, CATL, SK On) and select OEMs (Tesla via direct supply agreements) [S4]. The segment is **vertically integrated**: ALB owns equity stakes in or operates the resource (Atacama brine in Chile via a 50/50 partnership structure with SQM-style royalty to CORFO; Greenbushes via 49% Talison JV with Tianqi/IGO; Wodgina via 50/50 MARBL JV with Mineral Resources) and the conversion plants (Kemerton, Australia; La Negra, Chile; multiple China JV conversion facilities) [S2][S5]. Pricing has shifted from largely fixed-price multi-year contracts (pre-2022) toward index-linked / variable pricing on ~75–80% of book today, which means full commodity exposure on the upside *and* downside [S6].

**Segment 2 — Specialties (bromine + specialty lithium):** Bromine-based flame retardants (electronics housings, automotive plastics), oilfield clear brines (drilling fluids), pharmaceutical intermediates, and specialty lithium grades for grease, polymers, and pharma [S2]. Resource base: Smackover Formation brine in Magnolia, Arkansas and Dead Sea operations [S2]. The bromine market is a 3-player global oligopoly (Albemarle, ICL Group, Jordan Bromine) — pricing has been stable with mid-single-digit annual escalation, and the segment has delivered ~$1.0–1.1B revenue at ~25–30% gross margin through the entire 2020–2025 cycle [S7].

**Segment 3 — Ketjen (DIVESTED March 2026):** Was the refining-catalysts business (FCC for gasoline, hydroprocessing for cleaner fuels). Sold to KPS Capital Partners (renamed ChemCat) on March 2, 2026 for ~$547M; the 50% Eurecat JV (regeneration services) was sold to Axens in January 2026 for ~$123M; combined ~$670M [S3]. Proceeds were applied to debt reduction (long-term debt fell from $3,194M YE 2025 to $1,882M TTM Q1 2026) [S8].

**Value-chain layer map:**

| Layer | Energy Storage (lithium) | Specialties (bromine) |
|-------|--------------------------|------------------------|
| Resource | Atacama brine (CL), Greenbushes/Wodgina (AUS), Silver Peak (US) | Smackover brine (Arkansas), Dead Sea |
| Conversion | Kemerton, La Negra, China JVs | Magnolia AR, Dead Sea plants |
| Specialty processing | LiOH/Li₂CO₃/LiCl grades, battery-quality material | Flame retardants, clear brines, pharma intermediates |
| Customer | Tier-1 cell makers, EV OEMs | Electronics, oil & gas, pharma, polymers |
| Pricing | ~75–80% index-linked/variable; balance fixed multi-year | Mid-single-digit annual price escalation |

**Why this matters:** ALB's competitive position is *resource-position* + *conversion scale*, not branding or switching costs. The downside cycle (2023–2025) demonstrated that customer relationships do not protect realized prices — when LCE spot prices collapsed from ~$80/kg to ~$8–10/kg, ALB's realized prices followed, and gross margins compressed from 42% to 1.2% [S1][S6]. The franchise is real, but its earning power is **structurally cyclical** unless the company can shift pricing structure (more fixed-price) or unless lithium spot prices stabilize at a higher floor.

#### Evidence and Sources

- Segment revenue split: Energy Storage $3,800M / Specialties $1,100M / Ketjen ~$240M (thru Nov 2025) of FY2025 $5,143M revenue [S1].
- Ketjen sale: completed March 2, 2026; combined proceeds with Eurecat ~$670M; debt reduction confirmed in Q1 2026 10-Q [S3][S8].
- Pricing mix shift: ALB management commentary in 8-K releases through 2023–2024 confirmed variable/index pricing now dominates the book [S6].
- Bromine stability: Specialties revenue $1,000–1,200M annually 2020–2025; gross margin compression in cyclical lithium did not flow through to Specialties [S7].

#### Assumption Register Updates

| ID | Assumption | Change |
|----|-----------|--------|
| A05 | Energy Storage = ~75% of 2025 revenue | Confirmed (Energy Storage $3.8B / Specialties $1.1B / Ketjen $0.24B = $5.14B) |
| (new) A21 | Variable/index pricing share of lithium book: ~75–80% | Estimate, High sensitivity — drives cyclical exposure |
| (new) A22 | Bromine segment is a structural 3-player oligopoly | Judgment, Medium sensitivity — supports stable-floor thesis |

#### Tables and Calculations

**FY2025 Segment Revenue Split**

| Segment | Revenue ($M) | % of Total | Gross-margin profile |
|---------|-------------|-----------|---------------------|
| Energy Storage | ~3,800 | 74% | Cyclical: 1–42% range |
| Specialties | ~1,100 | 21% | Stable: 25–30% |
| Ketjen (divested) | ~240 (thru Nov '25) | 5% | ~20% (steady) |
| **Total** | **5,143** | **100%** | — |

#### Open Questions and Data Gaps

1. Exact mix of fixed-price vs. variable/index lithium contracts — disclosed only directionally.
2. Per-asset cash production cost (Atacama vs. Greenbushes vs. Kemerton vs. Wodgina) — needed for cost-curve positioning in Step 09/10.
3. Whether bromine pricing power is degrading at the margin (electronics flame-retardant substitution risk).

#### Source Index

| Source Tag | Document or URL | Section / Page / Slide | Date | Notes |
|------------|----------------|----------------------|------|-------|
| [S1] | SEC XBRL CIK 0000915913 | Annual concepts | 2026-05-27 | Revenue & margin history |
| [S2] | SEC 10-K FY2025 | Business section | filed Feb 2026 | Segment descriptions |
| [S3] | SEC 8-K | Ketjen sale close | 2026-03-02 | Combined proceeds ~$670M |
| [S4] | Industry market overview | industry/market_overview.md | 2026-05-27 | Tier-1 customer list |
| [S5] | SEC 10-K FY2025 | JV disclosures | filed Feb 2026 | Talison/MARBL/CORFO structure |
| [S6] | SEC 8-K FY2023–FY2024 | Earnings releases | 2024–2025 | Variable pricing share commentary |
| [S7] | SEC 10-K segments | Specialties segment | FY2020–FY2025 | Revenue + margin stability |
| [S8] | SEC 10-Q Q1 2026 | Debt footnotes | filed May 2026 | LT debt $1,882M post-Ketjen sale |

## Financial Snapshot

---
step: "04"
title: "Financial Quality & Adversarial Sweep"
ticker: ALB
company: "Albemarle Corporation"
source: coverage-next-full
created: 2026-05-28
---

### Step 04 — Financial Quality & Adversarial Sweep: ALB

#### Key Findings

- **GAAP accounting is largely conservative and standard** for the industry; revenue recognition follows shipment / delivery, no signs of channel stuffing or revenue acceleration [S1].
- **Impairment charges in 2024 ($1.03B) and 2025 ($280M)** were appropriate response to lithium price collapse — Kemerton Train 3 and Ketjen pre-sale carrying-value marks [S2]. Conservative impairment posture, not aggressive.
- **One material historical concern: FCPA settlement (2023, $103M)** related to pre-2010 payments in Vietnam/India/Indonesia. Company self-reported and remediated; independent compliance monitor was imposed [S3]. Risk: governance overhang, not ongoing material loss.
- **Net signal: positive on financial quality, with one significant historical compliance scar.**

#### Implications for Thesis and Valuation

Earnings quality through the cycle is **better than the headline numbers suggest**. The 2024–2025 GAAP losses are heavily weighted by non-cash impairments — underlying operating cash flow remained positive ($702M and $1,282M respectively) even at the bottom of the lithium cycle [S4]. This is critical for a Commodity/Upstream story: ALB demonstrated the ability to generate cash through a 90%+ price collapse, which de-risks the downside scenarios.

The FCPA settlement creates a small but persistent governance risk premium that should be reflected as ~50–100 bps additional cost of equity vs. a clean specialty-chemicals comp.

#### Objective

Assess earnings quality, accounting choices, restatements, and conduct the mandatory Adversarial Research Sweep (short reports, investigations, lawsuits, governance concerns).

#### Narrative Analysis

**Earnings quality scorecard:**

| Test | Result | Comment |
|------|--------|---------|
| OCF vs. Net Income | OCF >> NI in down years (2024: $702M OCF vs. ($1,179M) NI; 2025: $1,282M OCF vs. ($511M) NI) [S4] | Positive — losses are non-cash |
| Receivables vs. Revenue trend | Receivables tracking revenue declines proportionally [S1] | No buildup; clean |
| Inventory vs. Revenue | Inventory days elevated in 2024 (160+ days) as production exceeded demand; normalizing in 2025–2026 [S1] | Cyclical, not aggressive |
| SBC as % of OCF | SBC $40M / OCF $1.28B = 3% [S4] | Low; healthy |
| Capex vs. D&A | 2025 capex $590M vs. D&A $659M (capex < D&A — discipline) [S4] | Positive — investing below replacement |
| Goodwill vs. Equity | Goodwill $1,500M vs. Equity $9,533M = 16% [S1] | Manageable |
| Working-capital changes | Negative WC reversal in 2025 was OCF-positive ($580M) — inventory drawdown [S4] | One-time tailwind |

**Restatements / audit issues:** None material in 2020–2025 period [S1]. Auditor: PricewaterhouseCoopers (continuing engagement).

**Adversarial Research Sweep:**

| Item | Description | Status | Materiality |
|------|-------------|--------|-------------|
| **FCPA settlement (2023)** | $103M settlement with SEC/DOJ for pre-2010 anti-bribery violations in Vietnam, India, Indonesia. Self-reported, cooperated, paid disgorgement + penalty [S3] | Resolved with independent compliance monitor through ~2026 | Material historically; resolved |
| **Chile CORFO commission litigation risk** | No active litigation, but CORFO commissions paid ($232M in 2024) under tiered royalty structure; new Chile lithium law could alter terms post-2030 [S5] | Ongoing political risk | Material to long-term Chile resource access |
| **Short reports** | No known major short-seller report (Hindenburg, Muddy Waters, etc.) targeting ALB through May 2026 [S6] | None | N/A |
| **Class actions** | Standard securities class actions filed in 2024 related to lithium price disclosures (Kemerton ramp + capex guidance) — early-stage, no settlement [S7] | Ongoing | Likely immaterial individually |
| **Goodwill / asset impairments** | $1.03B (2024) + $280M (2025) — Kemerton Train 3 + Ketjen pre-sale marks; auditor-approved [S2] | Concluded | Non-cash; bookkeeping not concerning |
| **SBC creep** | $40M (2025); steady at 0.8% of revenue [S4] | Low | None |
| **Insider selling** | No significant insider selling at trough; equity-based comp vesting normal [S8] | Neutral | None |
| **Related-party transactions** | Standard JV arrangements (Talison with Tianqi/IGO; MARBL with Mineral Resources); arm's-length disclosed [S1] | None | None |
| **CFO turnover** | Stable; no recent CFO churn [S9] | None | None |

**Detailed FCPA notes:** The 2023 settlement related to payments made by intermediaries / agents to government officials in Vietnam, India, and Indonesia before 2010. Albemarle self-disclosed to DOJ in 2017–2018 and cooperated through investigation. The settlement included a deferred prosecution agreement (DPA), $103M in disgorgement + penalty, and a 2-year independent compliance monitorship (extending into 2026) [S3]. There is no evidence of repeat misconduct post-2010; the FCPA matter is contained, but creates ongoing reputational and regulatory monitoring overhead.

**Non-GAAP usage:** Albemarle reports adjusted EBITDA and adjusted EPS that exclude impairments, acquisition/divestiture-related items, and certain restructuring charges. The adjustments are clearly disclosed in earnings releases, and the magnitude of adjustments in 2024–2025 is large but documented [S10]. We will use adjusted EBITDA for cyclical comparison and GAAP net income for fundamental valuation.

#### Evidence and Sources

- OCF positive every year 2020–2025 even with GAAP losses — see xbrl_summary.md cash flow [S4].
- FCPA settlement $103M (2023) — public DOJ/SEC announcements [S3].
- Capex < D&A in 2025 ($590M vs. $659M) — discipline visible [S4].

#### Assumption Register Updates

| ID | Assumption | Change |
|----|-----------|--------|
| A06 | 2024 impairments drove ($1.18B) net loss | Confirmed; ~$1.03B of the loss was non-cash impairments |
| (new) A29 | OCF positive through the cycle ($702M+ even at trough) | Fact, Low sensitivity — anchors downside protection |
| (new) A30 | FCPA settlement risk premium: +50–100 bps to cost of equity | Judgment, Low sensitivity |

#### Tables and Calculations

**Earnings quality snapshot:**

| Metric | FY2022 | FY2023 | FY2024 | FY2025 | TTM Q1'26 |
|--------|--------|--------|--------|--------|----------|
| Net Income ($M) | 2,690 | 1,574 | (1,179) | (511) | (633) |
| OCF ($M) | 1,908 | 1,325 | 702 | 1,282 | 1,081 |
| OCF − NI ($M) | (782) | (249) | 1,881 | 1,793 | 1,714 |
| Impairments ($M) | 0 | 0 | 1,025 | 280 | 460 |
| Adj. Net Income (NI + Impair) | 2,690 | 1,574 | (154) | (231) | (173) |

The OCF-NI gap in 2024–2025 is almost entirely impairment-driven. Adjusted net income shows a much smaller actual loss footprint.

#### Open Questions and Data Gaps

1. Status of any FCPA-related residual obligations after monitorship ends (likely 2026).
2. Inventory carrying-value reserves at YE 2025 (vs. potential additional writedowns if lithium prices weaken again).
3. Class action status updates beyond initial complaints.

#### Source Index

| Source Tag | Document or URL | Section / Page / Slide | Date | Notes |
|------------|----------------|----------------------|------|-------|
| [S1] | SEC 10-K FY2025 | Financial statements + notes | filed Feb 2026 | Accounting policies |
| [S2] | SEC 10-K FY2024 + FY2025 | Impairment notes | filed 2025/2026 | Kemerton + Ketjen marks |
| [S3] | proxy/governance_and_compensation.md | SEC Settlement section | 2026-05-27 | FCPA $103M (2023) |
| [S4] | xbrl_summary.md | Cash flow + capex | 2026-05-27 | OCF, capex, SBC |
| [S5] | industry/market_overview.md | Chile CORFO | 2026-05-27 | Royalty payments |
| [S6] | Web search (Tavily) | Short reports | 2026-05-27 | No major shorts identified |
| [S7] | SEC 10-Q Q1 2026 | Legal proceedings | filed May 2026 | Class action mentions |
| [S8] | proxy/insider_transactions.md | Insider activity | 2026-05-27 | No selling at trough |
| [S9] | proxy/governance_and_compensation.md | Executives | 2026-05-27 | Stable management |
| [S10] | SEC 8-K Q4 2025, Q1 2026 | Non-GAAP reconciliation | 2026 | Adjusted EBITDA / EPS bridge |

## Recent Catalysts

---
step: "12"
title: "Bull vs Bear Debate (Analyst Framework)"
ticker: ALB
company: "Albemarle Corporation"
source: coverage-next-full
created: 2026-05-28
---

### Step 12 — Bull vs Bear: Albemarle Corporation (ALB)

> Filings-and-consensus path. **No earnings-call transcripts loaded** — the bull/bear debate is reconstructed from sell-side consensus, press releases, 10-K disclosures, and recent news rather than management-call commentary.

---

#### 1. Debate Context

Consensus rating: **Buy** with $215.95 average price target vs. ~$179 current (+21% upside).

| Rating Bucket | Count |
|---------------|-------|
| Strong Buy | 9 |
| Buy | 2 |
| Hold | 13 |
| Sell | 0 |

The Buy/Hold split (~46% Buy, 54% Hold) reflects a market that has shifted from "Sell — value trap" (peak bear of 2024) to "constructive — recovery underway but sustainability uncertain." Target dispersion is wide: $145-$264, implying ~75% range in valuation views — entirely a function of lithium price assumptions.

[S1]

---

#### 2. The Bull Argument (Long ALB)

##### Bull Premise
The lithium cycle has turned in early 2026, EV demand growth is structural, ALB has rightsized cost structure and balance sheet, and the next 3-5 years of sustained $15-25/kg LCE pricing produces $2.0-3.5B annual EBITDA versus $20B EV — a compressed multiple set to re-rate.

##### Bull Evidence
1. **Q1 2026 print is concrete:** $17/kg realized pricing, +51% YoY, +14% volumes, adj EBITDA $565M (~40% margin) [S2]. First positive operating quarter since Q2 2023.
2. **Balance sheet de-risked:** Net debt cut from $2.6B → $792M in 18 months [S3][S4]. Ketjen sale closed ($670M total proceeds). Revolver $1.5B undrawn.
3. **Capex discipline:** Slashed from $2.15B (2023) → $590M (2025) [S3]. Capital cycle now favors incumbent — Chinese capacity additions slowing as marginal cost producers shut.
4. **Resource quality:** Atacama brine + Greenbushes JV are best-in-world assets. At sustained $20+/kg LCE, ROIC returns to 15-20%+.
5. **EV demand structural:** Global EV penetration ~17-20% in 2025 → expected 35%+ by 2030 [S5]. Lithium demand doubles by 2030.
6. **IRA tailwind:** ALB is one of few non-China supply alternatives with scale; Kings Mountain + Wodgina + Greenbushes-sourced material is IRA-eligible.
7. **2026 guidance:** ~$2.5B adj EBITDA at Q1 pricing — implies ~8.4x EV/EBITDA at current $179/share. If 2027-2028 EBITDA approaches $3-3.5B, multiple compresses to 6x.

##### Bull Target Math
- 2027E adj EBITDA: ~$3.0B (assumes $18-20/kg avg + 5% volume growth)
- Target EV/EBITDA: 8x mid-cycle (vs. ~6x trough; vs. ~12x peak)
- Target EV: ~$24B
- Less: net debt ~$500M (continued de-leveraging)
- Less: mandatory convertible preferred dilution (~+33M shares Mar 2027)
- Target market cap: ~$23.5B / ~150M shares = **~$157/share** at 8x EV/EBITDA mid-cycle base case
- Bull scenario: 10x multiple × $3.5B EBITDA = $35B / 150M shares = **~$232/share**

---

#### 3. The Bear Argument (Short / Avoid ALB)

##### Bear Premise
The Q1 2026 lithium price spike is an artifact of (a) variable-pricing contract re-indexing to a brief Q4 2025 spot rally, (b) inventory destocking, and (c) Chinese restocking ahead of expected tariff increases — not sustainable demand pull. Chinese producers will respond to any sustained $15+/kg pricing with another wave of capacity, and ALB's mid-cost-curve position + March 2027 ~33% dilution make this a value trap.

##### Bear Evidence
1. **Variable-pricing lag:** ALB's ~80% variable book lags spot by 3-6 months. Q1 2026 realized $17/kg reflects spot prints from Q4 2025/early Q1 2026. Spot has been weaker since [S2] — Q2-Q4 2026 realizations may regress to $13-15/kg, undercutting guidance.
2. **Chinese supply discipline = temporary:** State-influenced Chinese producers (Ganfeng, Tianqi, smaller) idled marginal capacity in 2025. At $15+/kg, restart economics work — capacity returns and re-saturates.
3. **Mid-curve cost position:** ALB is not best-in-class on cost. Kemerton/Wodgina hard-rock conversion vs. Chinese integrated lepidolite/spodumene = persistent cost gap.
4. **Mandatory convertible preferred ~33% dilution March 2027:** Per-share value destruction baked in. Bull EBITDA scenarios must be discounted ~25-30% for dilution.
5. **Chile risk:** CORFO renegotiation 2027-2029 likely raises royalty/commission rates. Conservative scenario: Chile EBITDA contribution reduced 20-30%.
6. **Through-the-cycle ROIC < WACC:** Empirically, ALB has destroyed value through the full cycle (~5% ROIC vs. ~11% WACC over 5 years). Why does this cycle differ?
7. **Substitution risk:** Sodium-ion batteries (CATL deploying) reduce Li intensity in mass-market EVs; silicon anodes change LiOH/Li2CO3 mix.
8. **Trough EBITDA still possible:** At $10/kg sustained, ALB EBITDA is ~$500-700M, FCF ~break-even, dividend pressured.

##### Bear Target Math
- 2027E adj EBITDA (bear): ~$1.5B (lithium back to $13/kg avg)
- Target EV/EBITDA: 7x (cycle skepticism)
- Target EV: ~$10.5B
- Less: net debt ~$1.5B (rises if FCF disappoints)
- Less: mandatory convertible dilution (~+33M shares March 2027)
- Target market cap: ~$9B / 150M shares = **~$60/share**

---

#### 4. Where the Debate Crystallizes

The bull and bear differ primarily on **3 questions**:

| Question | Bull View | Bear View |
|----------|-----------|-----------|
| Sustainability of lithium pricing > $15/kg | Yes (structural demand) | No (Chinese capacity response) |
| Marginal cost position of Chinese producers | Above $12/kg (sets price floor) | Below $10/kg (long-term floor lower) |
| Through-the-cycle multiple ALB deserves | 8-10x EV/EBITDA | 5-7x EV/EBITDA |

Note: NEITHER side disputes the bromine business value (~$1B+ EBITDA durable). The debate is entirely about lithium.

---

#### 5. Variant Perception Setup

The most interesting variant view — neither pure bull nor bear:

> "Q1 2026 pricing is partially transitory but base-rate lithium has set a $13-16/kg structural floor (vs. the bear's $8-12). At this floor, ALB generates $1.5-2.0B normalized EBITDA, the bromine business is worth ~$5B standalone (10x EBITDA on $500M), so the lithium-attributable EV is ~$15B implying ~$10/per-LCE-tonne capacity. That's roughly fair value — neither cheap nor expensive. Re-rating requires either: (a) sustained $20+/kg pricing for 4+ quarters, or (b) major industry consolidation removing 100-200kt of high-cost capacity."

This is the realistic centrist view. See Step 16 for full variant-perception treatment.

---

#### 6. Catalysts Calendar (12 Months Forward)

| Date | Event | Direction |
|------|-------|-----------|
| Q2 2026 earnings (early Aug 2026) | Sustainability test for Q1 pricing | High-stakes binary |
| Q3 2026 earnings (early Nov 2026) | Second confirmation if positive | Bull-supporting if good |
| H2 2026 | China lithium supply commentary; restart signals | Bear-supporting if confirmed |
| FY2026 guidance refresh (Q2 print) | Likely upward revision if Q1 sustains | Bull-supporting |
| Q4 2026 / Q1 2027 | CORFO contract renegotiation signals | Risk event |
| March 2027 | Mandatory convertible preferred conversion | Confirmed dilution event |
| 2027 | Kings Mountain (NC) construction decisions | Long-dated tailwind |

---

#### 7. Bull Case — 3 Bullets

- **Cycle inflection confirmed in Q1 2026:** $17/kg realized, +51% YoY, $565M EBITDA on $1.4B revenue (40% margin); first profitable operating quarter since Q2 2023, and full-year 2026 guidance of $2.5B EBITDA at Q1 pricing implies ~8x EV/EBITDA on current price [S2][S6].
- **Balance sheet de-risked:** Net debt cut 70% to $792M (from $2.6B) via Ketjen sale ($670M proceeds), capex collapse ($2.15B → $590M), and positive FCF ($693M in 2025). $1.5B undrawn revolver + 1.1B cash = ample dry powder; no covenant pressure [S3][S4].
- **Best-in-world resource base + IRA tailwind:** Atacama brine + Greenbushes JV are top-tier global assets at the bottom of the cost curve; Kings Mountain + Wodgina deliver IRA-eligible US-allied supply at a time of accelerating supply-chain decoupling, supporting a premium multiple vs. China-dominated peers [S1][S5].

#### 8. Bear Case — 3 Bullets

- **Q1 2026 pricing is transitory:** ~80% variable contract book lags spot 3-6 months; Q1 realized $17/kg reflects Q4 2025/early Q1 2026 spot prints that have already softened. H2 2026 realizations may regress to $13-15/kg, undercutting guidance — and Chinese marginal-cost producers will restart capacity at any sustained $15+/kg, capping the cycle [S2][S5].
- **Through-the-cycle ROIC < WACC + ~33% dilution incoming:** 5-year average ROIC ~5% vs. WACC ~11% empirically destroys value. The mandatory convertible preferred converts in March 2027 adding ~32-39M shares (27-33% per-share dilution) — bull EBITDA scenarios must be discounted accordingly, materially compressing per-share upside [S3][S4].
- **Chile + China dual exposure:** ~25-30% of production exposed to CORFO renegotiation 2027-2029 (likely higher royalty/state-equity terms); ~30-40% of revenue China-exposed amid US FEOC/decoupling pressures; both regulatory regimes trend negatively for ALB's economics, with no clear management hedge [S1][S5].

---

#### 9. Source Index

| Tag | Source |
|-----|--------|
| S1 | ALB_financials/other/consensus.md (analyst ratings, targets) |
| S2 | SEC 8-K Q1 2026; acc 0000915913-26-000070 |
| S3 | ALB_financials/xbrl/xbrl_summary.md |
| S4 | SEC 10-K FY2025; acc 0000915913-26-000018 |
| S5 | ALB_financials/industry/market_overview.md |
| S6 | SEC 10-Q Q1 2026; acc 0000915913-26-000072 |

## Full Research Available

This primer covers steps 1–3 of 19. The full deep dive (moat analysis, DCF, bull/bear,
management quality, earnings transcript analysis) is available via:

- Investment memo: /memo/alb
- Full research API: GET /api/v1/research/ALB/memo
- Coverage universe: /stocks